中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

10 records (took 0.014 seconds)

    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING MAGE-A
    1.
    发明申请
    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING MAGE-A 有权

    公开(公告)号：US20210032361A1

    公开(公告)日：2021-02-04

    申请号：US16943779

    申请日：2020-07-30

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Meike HUTT ,  Felix UNVERDORBEN ,  Sebastian BUNK ,  Dominik MAURER ,  Martin HOFMANN ,  Gabriele PSZOLLA ,  Sara YOUSEF ,  Claudia WAGNER ,  Frank SCHWOEBEL ,  Heiko SCHUSTER

    IPC: C07K16/30 ,  C07K14/725 ,  A61P35/00

    Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME
    6.
    发明申请
    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME 有权

    公开(公告)号：US20230091330A1

    公开(公告)日：2023-03-23

    申请号：US17934303

    申请日：2022-09-22

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Gabriele PSZOLLA ,  Martin HOFMANN ,  Meike HUTT ,  Sebastian BUNK ,  Felix UNVERDORBEN ,  Frank SCHWOEBEL ,  Dominik MAURER ,  Maike JAWORSKI ,  Claudia WAGNER ,  Florian SCHWOERER ,  Heiko SCHUSTER

    IPC: C07K16/30 ,  C07K16/28 ,  C07K16/46

    Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME
    8.
    发明申请
    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME 有权

    公开(公告)号：US20230132241A1

    公开(公告)日：2023-04-27

    申请号：US17793237

    申请日：2020-01-15

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Sebastian BUNK ,  Martin HOFMANN ,  Meike HUTT ,  Dominik MAURER ,  Gabriele PSZOLLA ,  Frank SCHWOEBEL ,  Felix UNVERDORBEN ,  Claudia WAGNER ,  Sara YOUSEF

    IPC: C07K16/30 ,  C12N15/63 ,  A61P35/00

    Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are selective and specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 8 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME
    9.
    发明申请
    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME 有权

    公开(公告)号：US20220372165A1

    公开(公告)日：2022-11-24

    申请号：US17736882

    申请日：2022-05-04

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Gabriele PSZOLLA ,  Martin HOFMANN ,  Meike HUTT ,  Sebastian BUNK ,  Felix UNVERDORBEN ,  Frank SCHWOEBEL ,  Dominik MAURER ,  Maike JAWORSKI ,  Claudia WAGNER ,  Florian SCHWOERER ,  Heiko SCHUSTER

    IPC: C07K16/30 ,  C07K16/46 ,  C07K16/28

    Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

    RECRUITING AGENT FURTHER BINDING AN MHC MOLECULE
    10.
    发明申请
    RECRUITING AGENT FURTHER BINDING AN MHC MOLECULE 有权

    公开(公告)号：US20210032370A1

    公开(公告)日：2021-02-04

    申请号：US16943313

    申请日：2020-07-30

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Gabriele PSZOLLA ,  Martin HOFMANN ,  Felix UNVERDORBEN ,  Meike HUTT ,  Dominik MAURER ,  Sebastian BUNK

    IPC: C07K16/46 ,  C07K16/28 ,  C07K16/32

    Abstract: The present invention concerns bispecific antigen binding proteins directed against MHC presented target antigens (TA). The invention in particular provides bispecific antigen binding proteins comprising at least two antigen binding sites (A and B), wherein the antigen binding site A binds to CD3 and the antigen binding site B binds to a target antigenic (TA) peptide/MHC complex. The bispecific antigen binding proteins of the invention comprise, in particular, the CDRs of the VL and VH domains of novel engineered anti-CD3 antibodies having a reduced affinity. The bispecific antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of TA associated diseases, such as tumor-associated antigen (TAA) expressing cancerous diseases. Further provided are nucleic acids encoding the bispecific antigen binding protein of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding protein and pharmaceutical compositions comprising the bispecific antigen binding proteins of the invention.

Patent Agency Ranking